{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T05:02:42Z","timestamp":1792213362330,"version":"4.4.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.urolonc.2025.05.016","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T03:15:59Z","timestamp":1751426159000},"page":"595.e1-595.e11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Enfortumab vedotin-related skin toxicities in patients with urothelial carcinoma: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0300-7991","authenticated-orcid":false,"given":"Gabriela","family":"Gazzoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Michelon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maysa","family":"Vilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Pedro","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Inez","family":"Dacoregio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro C.\u202fA.","family":"Reis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo A.\u202fP.","family":"Braga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara Aleixo","family":"Sim\u00f5es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilia Maria Lima","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Zibelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Paula","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.urolonc.2025.05.016_bib0001","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.urolonc.2025.05.016_bib0002","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/CU9.0000000000000204","article-title":"Enfortumab vedotin and pembrolizumab as monotherapies and combination treatment in locally advanced or metastatic urothelial carcinoma: a narrative review","volume":"17","author":"Bantounou","year":"2023","journal-title":"Curr Urol"},{"issue":"29","key":"10.1016\/j.urolonc.2025.05.016_bib0003","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1200\/JCO.19.01140","article-title":"Pivotal Trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1\/programmed death ligand 1 therapy","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.05.016_bib0004","unstructured":"National Cancer Institute. Cancer Stat Facts: Bladder Cancer. Bethesda (MD): National Cancer Institute; 2021. https:\/\/seer.cancer.gov\/statfacts\/html\/urinb.html. Accessed 29.07.2021."},{"key":"10.1016\/j.urolonc.2025.05.016_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2010\/207084","article-title":"Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review","volume":"2010","author":"Makrilia","year":"2010","journal-title":"Met-Based Drugs"},{"issue":"40","key":"10.1016\/j.urolonc.2025.05.016_bib0006","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1200\/EDBK_289911","article-title":"Dermatologic Adverse events of systemic anticancer therapies: cytotoxic chemotherapy, targeted therapy, and immunotherapy","author":"Deutsch","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"2","key":"10.1016\/j.urolonc.2025.05.016_bib0007","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nrurol.2017.190","article-title":"Immunotherapy in metastatic urothelial carcinoma: focus on immune checkpoint inhibition","volume":"15","author":"Siefker-Radtke","year":"2018","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.urolonc.2025.05.016_bib0008","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.2147\/OTT.S370900","article-title":"Targeted Treatment of Locally advanced and metastatic urothelial cancer: enfortumab vedotin in context","volume":"15","author":"Hoffman-Censits","year":"2022","journal-title":"OncoTargets Ther"},{"key":"10.1016\/j.urolonc.2025.05.016_bib0009","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.euros.2023.04.018","article-title":"Enfortumab vedotin in metastatic urothelial carcinoma: survival and safety in a European multicenter real-world patient cohort","volume":"53","author":"Zsch\u00e4bitz","year":"2023","journal-title":"Eur Urol Open Sci"},{"issue":"6","key":"10.1016\/j.urolonc.2025.05.016_bib0010","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S1470-2045(21)00094-2","article-title":"Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV\u2011201): a multicentre, single-arm, phase 2 trial","volume":"22","author":"Yu","year":"2021","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2025.05.016_bib0011","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15030713","article-title":"Mechanisms of ADC toxicity and strategies to increase ADC tolerability","volume":"15","author":"Nguyen","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.urolonc.2025.05.016_bib0012","doi-asserted-by":"crossref","first-page":"e223","DOI":"10.1093\/oncolo\/oyac001","article-title":"Management of dermatologic events associated with the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin","volume":"27","author":"Lacouture","year":"2022","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.urolonc.2025.05.016_bib0013","doi-asserted-by":"crossref","first-page":"9717","DOI":"10.18632\/oncotarget.14206","article-title":"The expression of Nectin-4 on the surface of ovarian cancer cells alters their ability to adhere, migrate, aggregate, and proliferate","volume":"8","author":"Boylan","year":"2017","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.urolonc.2025.05.016_bib0014","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41585-020-00394-5","article-title":"The biology and rationale of targeting nectin-4 in urothelial carcinoma","volume":"18","author":"Heath","year":"2021","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.urolonc.2025.05.016_bib0015","unstructured":"Higgins J.P.T., Thomas J., Chandler J., Cumpston M., Li T., Page M.J., editors. Cochrane Handbook for Systematic Reviews of Interventions. Version 6.4 (updated August 2023). Cochrane; 2023. Available from:. www.training.cochrane.org\/handbook. Accessed 06.02.2024."},{"key":"10.1016\/j.urolonc.2025.05.016_bib0016","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.urolonc.2025.05.016_bib0017","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 Published: MAY 28, 2009. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES. National Institutes of Health https:\/\/www.eortc.be\/services\/doc\/ctc\/ctcae_4.03_2010-06-14_quickreference_5\u00d77.pdf (Accessed 20.02.2024)."},{"key":"10.1016\/j.urolonc.2025.05.016_bib0018","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 Published: November 27, 2017. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES. National Institutes of Healthhttps:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5\u00d711.pdf Accessed 20.02.2024."},{"issue":"7","key":"10.1016\/j.urolonc.2025.05.016_bib0019","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2165\/00002018-200730070-00009","article-title":"Standardised MedDRA Queries: their role in signal detection","volume":"30","author":"Mozzicato","year":"2007","journal-title":"Drug Saf"},{"key":"10.1016\/j.urolonc.2025.05.016_bib0020","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.urolonc.2025.05.016_bib0021","unstructured":"Wells G.A., Shea B., O\u2019Connell D., Peterson J., Welch V., Losos M., et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.htm. Accessed 01.06.2024."},{"issue":"4","key":"10.1016\/j.urolonc.2025.05.016_bib0022","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid Based Ment Health"},{"issue":"11","key":"10.1016\/j.urolonc.2025.05.016_bib0023","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.annonc.2023.08.016","article-title":"EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma","volume":"34","author":"Rosenberg","year":"2023","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2025.05.016_bib0024","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1007\/s10637-019-00844-x","article-title":"A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma","volume":"38","author":"Takahashi","year":"2020","journal-title":"Invest New Drugs"},{"issue":"10","key":"10.1016\/j.urolonc.2025.05.016_bib0025","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1200\/JCO.19.02044","article-title":"EV-101: a Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma","volume":"38","author":"Rosenberg","year":"2020","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"25","key":"10.1016\/j.urolonc.2025.05.016_bib0026","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1200\/JCO.22.02887","article-title":"Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer","volume":"41","author":"O\u2019Donnell","year":"2023","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2025.05.016_bib0027","doi-asserted-by":"crossref","first-page":"759","DOI":"10.3390\/curroncol31020056","article-title":"Real-World Insights into Efficacy and Safety of Enfortumab Vedotin in Japanese Patients with Metastatic Urothelial Carcinoma: Findings, Considerations, and Future Directions","volume":"31","author":"Endo","year":"2024","journal-title":"Curr Oncol"},{"key":"10.1016\/j.urolonc.2025.05.016_bib0028","article-title":"Real world evidence of enfortumab vedotin in patients with advanced urothelial cancer: a multicenter observational study","author":"Fukuokaya","year":"2023","journal-title":"Int J Urol Off J Jpn Urol Assoc"},{"issue":"9","key":"10.1016\/j.urolonc.2025.05.016_bib0029","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.21873\/anticanres.16594","article-title":"Efficacy and tolerability of Enfortumab vedotin for metastatic urothelial carcinoma: early experience in the real world","volume":"43","author":"Minato","year":"2023","journal-title":"Anticancer Res"},{"key":"10.1016\/j.urolonc.2025.05.016_bib0030","first-page":"hyad170","article-title":"Enfortumab vedotin following platinum-based chemotherapy and immune checkpoint inhibitors for advanced urothelial carcinoma: response, survival and safety analysis from a multicentre real-world Japanese cohort","author":"Miyake","year":"2023","journal-title":"Jpn J Clin Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2025.05.016_bib0031","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s11523-024-01099-0","article-title":"Enfortumab Vedotin following platinum chemotherapy and avelumab maintenance in patients with metastatic urothelial carcinoma: a Retrospective Data from the ARON-2(EV) Study","volume":"19","author":"Fiala","year":"2024","journal-title":"Target Oncol"},{"issue":"7","key":"10.1016\/j.urolonc.2025.05.016_bib0032","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.21873\/anticanres.17115","article-title":"Cutaneous and renal toxicities of enfortumab vedotin for advanced urothelial carcinoma: the UROKYU study","volume":"44","author":"Furubayashi","year":"2024","journal-title":"Anticancer Res"},{"issue":"6","key":"10.1016\/j.urolonc.2025.05.016_bib0033","first-page":"696","article-title":"Clinical outcomes in patients with advanced urothelial carcinoma treated with enfortumab vedotin: a retrospective multicenter study in Japan","volume":"31","author":"Hara","year":"2024","journal-title":"Int J Urol Off J Jpn Urol Assoc"},{"issue":"11","key":"10.1016\/j.urolonc.2025.05.016_bib0034","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/jjco\/hyae082","article-title":"Association between response to enfortumab vedotin and peripheral neuropathy in urothelial carcinoma patients: a multicenter retrospective study","volume":"54","author":"Hayakawa","year":"2024","journal-title":"Jpn J Clin Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2025.05.016_bib0035","doi-asserted-by":"crossref","first-page":"783","DOI":"10.21873\/cdp.10396","article-title":"Risk Classification of patients with advanced urothelial carcinoma treated with enfortumab vedotin","volume":"4","author":"Ishikawa","year":"2024","journal-title":"Cancer Diagn Progn"},{"issue":"4","key":"10.1016\/j.urolonc.2025.05.016_bib0036","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.eururo.2022.12.009","article-title":"In patients with advanced urothelial carcinoma, immune checkpoint inhibition prior to enfortumab vedotin is associated with high-grade skin toxicity","volume":"83","author":"Molina","year":"2023","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.urolonc.2025.05.016_bib0037","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16091725","article-title":"C-Reactive protein is a potential prognostic marker in patient with advanced or metastatic urothelial carcinoma treated with Enfortumab vedotin: a multi-center retrospective study","volume":"16","author":"Morikawa","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.urolonc.2025.05.016_bib0038","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s10147-024-02672-3","article-title":"Treatment-related skin reactions in enfortumab vedotin as a surrogate marker of survival and treatment response","volume":"30","author":"Nagayama","year":"2025","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.05.016_bib0039","doi-asserted-by":"crossref","first-page":"102301","DOI":"10.1016\/j.clgc.2025.102301","article-title":"Enfortumab Vedotin for Metastatic Urothelial Carcinoma: Comprehensive Treatment Outcomes and Prognostic Insights From a Multicenter Real-World Study (YUSHIMA Study)","author":"Nakamura","year":"2025","journal-title":"Clin Genitourin Cancer"},{"issue":"15","key":"10.1016\/j.urolonc.2025.05.016_bib0040","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16152648","volume":"16","author":"Nakane","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.urolonc.2025.05.016_bib0041","doi-asserted-by":"crossref","first-page":"102278","DOI":"10.1016\/j.clgc.2024.102278","article-title":"Real-world evidence for enfortumab vedotin in patients with metastatic urothelial cancer: an Austrian multicentre study","volume":"23","author":"Niedersuess-Beke","year":"2025","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2025.05.016_bib0042","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jdin.2022.10.004","article-title":"Characterization of cutaneous adverse events to enfortumab vedotin: a retrospective case-control study","volume":"10","author":"Shahin","year":"2023","journal-title":"JAAD Int"},{"issue":"2","key":"10.1016\/j.urolonc.2025.05.016_bib0043","doi-asserted-by":"crossref","first-page":"102183","DOI":"10.1016\/j.jgo.2024.102183","article-title":"Efficacy and safety of enfortumab vedotin in older patients with metastatic urothelial carcinoma: a multicenter retrospective study","volume":"16","author":"Shindo","year":"2025","journal-title":"J Geriatr Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2025.05.016_bib0044","doi-asserted-by":"crossref","first-page":"224","DOI":"10.5114\/wo.2023.134751","article-title":"First experience in treating advanced urothelial cancer with enfortumab vedotin. Single-centre retrospective study of patients qualified for a rescue access procedure","volume":"27","author":"Sikora-Kupis","year":"2023","journal-title":"Wspolczesna Onkol"},{"key":"10.1016\/j.urolonc.2025.05.016_bib0045","article-title":"Physical, but not laboratory, treatment-related adverse events are associated with favorable outcomes of enfortumab vedotin for advanced urothelial carcinoma: A landmark analysis","author":"Taguchi","year":"2024","journal-title":"Int J Urol Off J Jpn Urol Assoc"},{"issue":"5","key":"10.1016\/j.urolonc.2025.05.016_bib0046","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1007\/s10147-024-02481-8","article-title":"Peripheral neuropathy and nerve electrophysiological changes with enfortumab vedotin in patients with advanced urothelial carcinoma: a prospective multicenter cohort study","volume":"29","author":"Taoka","year":"2024","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.05.016_bib0047","doi-asserted-by":"crossref","DOI":"10.1007\/s11523-024-01047-y","article-title":"Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint Inhibitors","author":"Uchimoto","year":"2024","journal-title":"Target Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2025.05.016_bib0048","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/iju.15437","article-title":"Enfortumab vedotin prolongs overall survival in metastatic urothelial carcinoma following pembrolizumab therapy in real-world data","volume":"31","author":"Uemura","year":"2024","journal-title":"Int J Urol"},{"key":"10.1016\/j.urolonc.2025.05.016_bib0049","doi-asserted-by":"crossref","first-page":"1377842","DOI":"10.3389\/fonc.2024.1377842","article-title":"Enfortumab vedotin-related cutaneous toxicity correlates with overall survival in patients with urothelial cancer: a retrospective experience","volume":"14","author":"Vlachou","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.urolonc.2025.05.016_bib0050","unstructured":"Seagen, Astellas Pharma US Inc. PADCEV (enfortumab vedotin-ejfv) for injection (2023). https:\/\/astellas.us\/docs\/PADCEV_label.pdf (Accessed 9.06.2024)."},{"key":"10.1016\/j.urolonc.2025.05.016_bib0051","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jdcr.2023.10.025","article-title":"Enfortumab vedotin toxic epidermal necrolysis\u2013like blistering dermatosis: a case series and review of the literature","volume":"43","author":"Khanjar","year":"2024","journal-title":"JAAD Case Rep"},{"issue":"4","key":"10.1016\/j.urolonc.2025.05.016_bib0052","doi-asserted-by":"crossref","first-page":"102975","DOI":"10.1016\/j.esmoop.2024.102975","article-title":"Association between skin toxicity and efficacy of necitumumab in squamous non-small-cell lung cancer: a pooled analysis of two randomized clinical trials-SQUIRE and JFCM","volume":"9","author":"Watanabe","year":"2024","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.urolonc.2025.05.016_bib0053","doi-asserted-by":"crossref","first-page":"100064","DOI":"10.1016\/j.esmoop.2021.100064","article-title":"Immune checkpoint inhibitor associated vitiligo and its impact on survival in patients with metastatic melanoma: an Italian Melanoma Intergroup study","volume":"6","author":"Guida","year":"2021","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.urolonc.2025.05.016_bib0054","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/1346-8138.13520","article-title":"Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: A multi-institutional retrospective study","volume":"44","author":"Nakamura","year":"2017","journal-title":"J Dermatol"},{"issue":"10","key":"10.1016\/j.urolonc.2025.05.016_bib0055","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab Vedotin and Pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2025.05.016_bib0056","unstructured":"U.S. Food and Drug Administration. FDA approves enfortumab vedotin-ejfv with pembrolizumab for locally advanced or metastatic urothelial cancer (2023). Available online at:https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-enfortumab-vedotin-ejfv-pembrolizumab-locally-advanced-or-metastatic-urothelial-cancer (Accessed 9.06.2024)."},{"key":"10.1016\/j.urolonc.2025.05.016_bib0057","doi-asserted-by":"crossref","first-page":"1326715","DOI":"10.3389\/fonc.2024.1326715","article-title":"Managing potential adverse events during treatment with enfortumab vedotin + pembrolizumab in patients with advanced urothelial cancer","volume":"14","author":"Brower","year":"2024","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.05.016_bib0058","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12874-021-01381-z","article-title":"Conducting proportional meta-analysis in different types of systematic reviews: a guide for synthesisers of evidence","volume":"21","author":"Barker","year":"2021","journal-title":"BMC Med Res Methodol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925002157?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925002157?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T13:26:50Z","timestamp":1757338010000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143925002157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":58,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1078143925002157"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.05.016","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enfortumab vedotin-related skin toxicities in patients with urothelial carcinoma: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.05.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}